Consistency of continual reassessment method under model misspecification
From MaRDI portal
Recommendations
- On the consistency of the continual reassessment method with multiple toxicity constraints
- A note on the robustness of the continual reassessment method
- A simple technique to evaluate model sensitivity in the continual reassessment method
- Continual reassessment and related dose-finding designs
- Miscellanea. A stopping rule for the continual reassessment method
Cited in
(40)- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Adaptive clinical trial designs for phase I cancer studies
- Theoretical study of the continual reassessment method
- A note on continual reassessment method
- Dose-finding designs for HIV studies
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
- Curve-free and model-based continual reassessment method designs
- A simple technique to evaluate model sensitivity in the continual reassessment method
- Continual reassessment method for ordered groups
- Characterization of the likelihood continual reassessment method
- Dynamic calibration of pharmacokinetic parameters in dose-finding studies
- Highest dose level for non-increased-toxicity response in longitudinal data
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- A note on the robustness of the continual reassessment method
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- On the consistency of the continual reassessment method with multiple toxicity constraints
- On multi-armed bandit designs for dose-finding trials
- scientific article; zbMATH DE number 7513920 (Why is no real title available?)
- A new design of the continual reassessment method
- Impact of different model structure and prior distribution in continual reassessment method
- A study of the probit model with latent variables in Phase I clinical trials
- The treatment versus experimentation dilemma in dose finding studies
- Retrospective Analysis of Sequential Dose‐Finding Designs
- Performance Measures in Dose‐Finding Experiments
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
- A simulation-free approach to assessing the performance of the continual reassessment method
- Incorporating patient-reported outcomes in dose-finding clinical trials
- Consistency of the when the curve is not monotone and its application to the POCRM
- Change-point joint model for identification of plateau of activity in early phase trials
- Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
- Dose finding with longitudinal data: simpler models, richer outcomes
- A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy
- Incorporating adverse event relatedness into dose-finding clinical trial designs
- Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials
- Dimension of model parameter space and operating characteristics in adaptive dose-finding studies
- Adaptive dose modification for phase I clinical trials
- A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials
- Identifying a maximum tolerated contour in two-dimensional dose finding
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Convergence properties of sequential Bayesian \(D\)-optimal designs
This page was built for publication: Consistency of continual reassessment method under model misspecification
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3837320)
